Andrew Benjamin Nixon, PhD

Associate Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Liu, Yingmiao, Mark D. Starr, John C. Brady, Christel Rushing, Anuradha Bulusu, Herbert Pang, Wanda Honeycutt, et al. “Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus..” Mol Cancer Ther 14, no. 4 (April 2015): 1048–56. https://doi.org/10.1158/1535-7163.MCT-14-0923-T.

PMID
25695956
Full Text

Cushman, Stephanie M., Chen Jiang, Ace J. Hatch, Ivo Shterev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kouros Owzar, Herbert I. Hurwitz, and Andrew B. Nixon. “Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)..” Clin Cancer Res 21, no. 5 (March 1, 2015): 1078–86. https://doi.org/10.1158/1078-0432.CCR-14-2313.

PMID
25520391
Full Text

Uronis, Hope E., Jingquan Jia, Johanna C. Bendell, Leigh Howard, Neal A. Ready, Paula H. Lee, Mark D. Starr, et al. “A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors..” Cancer Chemother Pharmacol 75, no. 2 (February 2015): 343–52. https://doi.org/10.1007/s00280-014-2647-x.

PMID
25527204
Full Text

Rushing, Christel, Anuradha Bulusu, Herbert I. Hurwitz, Andrew B. Nixon, and Herbert Pang. “A leave-one-out cross-validation SAS macro for the identification of markers associated with survival..” Comput Biol Med 57 (February 2015): 123–29. https://doi.org/10.1016/j.compbiomed.2014.11.015.

PMID
25553357
Full Text

Clarke, Jeffrey Melson, Herbert Pang, Mark D. Starr, Ace Joseph Hatch, Hedy Lee Kindler, Eileen Mary O’Reilly, Federico Innocenti, Alan P. Venook, Herbert Hurwitz, and Andrew B. Nixon. “Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance)..” In Journal of Clinical Oncology, 33:306–306. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.3_suppl.306.

Full Text

Secord, Angeles Alvarez, Andrew B. Nixon, and Herbert I. Hurwitz. “The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer..” Gynecol Oncol 135, no. 2 (November 2014): 349–58. https://doi.org/10.1016/j.ygyno.2014.08.033.

PMID
25178997
Full Text

Knelson, Erik H., Angela L. Gaviglio, Jasmine C. Nee, Mark D. Starr, Andrew B. Nixon, Stephen G. Marcus, and Gerard C. Blobe. “Abstract 2674: Stroma biology identifies heparins as differentiating agents in neuroblastoma.” In Experimental and Molecular Therapeutics. American Association for Cancer Research, 2014. https://doi.org/10.1158/1538-7445.am2014-2674.

Full Text

Liu, Yingmiao, Hongyu Tian, Gerard C. Blobe, Charles P. Theuer, Herbert I. Hurwitz, and Andrew B. Nixon. “Effects of the combination of TRC105 and bevacizumab on endothelial cell biology..” Invest New Drugs 32, no. 5 (October 2014): 851–59. https://doi.org/10.1007/s10637-014-0129-y.

PMID
24994097
Full Text

Bitting, Rhonda L., Patrick Healy, Patricia A. Creel, James Turnbull, Karla Morris, Sarah Yenser Wood, Herbert I. Hurwitz, et al. “A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma..” Clin Genitourin Cancer 12, no. 4 (August 2014): 241–50. https://doi.org/10.1016/j.clgc.2013.11.020.

PMID
24685058
Full Text

Rangwala, Fatima, Johanna C. Bendell, Mark F. Kozloff, Christy C. Arrowood, Andrew Dellinger, Jennifer Meadows, Sandra Tourt-Uhlig, et al. “Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors..” Invest New Drugs 32, no. 4 (August 2014): 700–709. https://doi.org/10.1007/s10637-014-0089-2.

PMID
24711126
Full Text

Pages